Takeda Pharmaceutical Company Limited

TAK

NYSE · Specialty & Generic Pharma

$18.81

At close - Sep 23, 4:00 PM EDT - USD

Market Cap$59.84B

P/E46.6x

52W High$19.10

Volume2.56M

VCP Research Verdict2026Q1

Plasma Business Masks Structural Margin and Growth Volatility

Takeda's investment case is a tug-of-war between its durable plasma-derived therapy infrastructure and a core innovative portfolio struggling to deliver consistent growth, as evidenced by revenue growth swinging from +14.1% to -5.4% over the past ten quarters....

GrowthMixed

ProfitabilityStrained

ValuationAttractive

TechnicalsStrong

Explore valuation models

MARKET ACTION

TAK price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis

Fundamental Trajectory

Revenue growth has been highly erratic, swinging from +14.1% in 2024Q1 to -5.4% in 2025Q2, while gross margins of 66.7% in 2026Q1 remain below innovative peers, suggesting the top line is driven by volatile product mix rather than sustainable organic momentum.

Analyst Consensus

Buy(6 analysts)

5 Buy1 Hold0 Sell

The Bull Case

Upside Catalysts

Successful clinical readouts

Positive outcomes from clinical trials could drive a re-rating of the stock towards analyst highs.

Clearer post-quarter guidance

Improved guidance following quarterly results may enhance investor confidence and stock performance.

Tangible cost-synergy realization

Achieving cost synergies could lead to improved margins and a re-rating of the stock.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

TAK+22.40%

S&P 500 (^GSPC)+12.39%

1-Year Return

TAK+29.09%

S&P 500 (^GSPC)+15.77%

3-Year Return

TAK+29.33%

S&P 500 (^GSPC)+75.26%

5-Year Return

TAK+28.40%

S&P 500 (^GSPC)+70.79%

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis

Trailing P/E5Y High

46.6x

Forward P/EExpansion

0.3x

EV/EBITDA100th %ile

10.3x

FCF YieldCash Flow

8.5%

Valuation vs 5-Year History

Multiple Range

Metric

Current

5Y Median

Historical Range

Percentile

P/E

46.6x

0.3x

100th· High

EV/EBITDA

10.3x

3.4x

100th· High

Price/FCF

11.7x

0.1x

100th· High

Current Multiple

5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection

Bear$37.37+98.7%

Base (Fair)$70.61+273.4%

Bull$88.03+368.0%

$37.37 Bear$70.61 Base$88.03 Bull

Current Market Price: $18.81

Trades at a 73.4% discount to Base DCF ($70.61)

Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend

Revenue

$4777.45B+4.3% YoY

Net income

$203.33B+88.4% YoY

Free cash flow

$808.7B-5.6% YoY

Operating margin

12%+4.5 pts YoY

ROIC (TTM)3.7%

Avg ROIC 5Y-

ROE (TTM)2.8%

Piotroski Score7 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate3/12 (27%)

Revenue Beat Rate7/12 (64%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest Jul 30, 2026	$0.23+33.2% vs $0.17	$7.7B+7.4% vs $7.1B
Q2 2026 May 13, 2026	-$0.05-123.4% vs $0.21	$6.9B-3.0% vs $7.1B
Q1 2026 Jan 29, 2026	$0.21-61.3% vs $0.55	$7.7B+2.5% vs $7.5B
Q4 2025 Oct 30, 2025	-$0.02-105.7% vs $0.44	$7.2B-7.3% vs $7.8B

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

5 Stories

Defense World·Sep 16, 2026

Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Takeda Pharmaceutical has a

Seeking Alpha·Sep 14, 2026

Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment Research·Sep 14, 2026

Best Value Stocks to Buy for September 14th

SIG, TAK and TX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 14th, 2026.

Zacks Investment Research·Sep 14, 2026

Best Income Stocks to Buy for September 14th

TX, HPQ and TAK made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 14th, 2026.

Filtered for Takeda Pharmaceutical Company LimitedMore Headlines

Compare before deciding

Benchmark TAK against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Takeda Pharmaceutical Company Limited (TAK)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
TAKTakeda Pharmaceutical Company LimitedCurrent	$18.81	$59.84B	46.61	4.28%	4.26%	2.76%	3.46%
NVONovo Nordisk A/S	$38.17	$169.5B	10.91	6.43%	35.35%	59.09%	—
AZNAstraZeneca PLC	$163.33	$126.58B	12.49	8.63%	17.02%	21.72%	—
SNYSanofi	$41.66	$100.03B	11.44	5.49%	8.09%	5.5%	—
NVSNovartis AG	$142.71	$271.25B	19.85	5.97%	22.93%	29.64%	—
GSKGSK plc	$49.71	$99.59B	13.51	4.11%	14.52%	24.99%	—

Compare TAK vs Peers

Takeda Pharmaceutical Company Limited (TAK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVO

Most directly comparable listed peer for TAK.

Scale Benchmark

vs LLY

Larger-name benchmark to compare TAK against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVO, AZN, SNY, NVS

Get notified when TAK posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

TAK Frequently Asked Questions

Takeda Pharmaceutical Company Limited (TAK) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Takeda Pharmaceutical Company Limited's revenue?

Takeda Pharmaceutical Company Limited (TAK) reported $4.66T in revenue for fiscal year 2025. This represents a 384% increase from $963.48B in 2000.

How fast is Takeda Pharmaceutical Company Limited growing?

Takeda Pharmaceutical Company Limited (TAK) grew revenue by 4.3% over the past year. Growth has been modest.

Is TAK profitable?

Yes, Takeda Pharmaceutical Company Limited (TAK) is profitable, generating $182.14B in net income for fiscal year 2025 (4.3% net margin).

Dividend & Returns

Does TAK pay dividends?

Yes, Takeda Pharmaceutical Company Limited (TAK) pays a dividend with a yield of 3.46%. This makes it attractive for income-focused investors.

What is TAK's return on equity?

Takeda Pharmaceutical Company Limited (TAK) has a return on equity (ROE) of 2.8%. This is below average, suggesting room for improvement.

What is Takeda Pharmaceutical Company Limited's free cash flow?

Takeda Pharmaceutical Company Limited (TAK) generated $524.08B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in TAK back in 2000?

Total return calculator · dividends reinvested · 26+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Jul 30, 2026

$0.23+33.2%

vs $0.17

$7.7B+7.4%

vs $7.1B

Q2 2026

May 13, 2026

-$0.05-123.4%

vs $0.21

$6.9B-3.0%

vs $7.1B

Q1 2026

Jan 29, 2026

$0.21-61.3%

vs $0.55

$7.7B+2.5%

vs $7.5B

Q4 2025

Oct 30, 2025

-$0.02-105.7%

vs $0.44

$7.2B-7.3%

vs $7.8B

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

TAKTakeda Pharmaceutical Company LimitedCurrent

$18.81

$59.84B

46.61

4.28%

4.26%

2.76%

3.46%

NVONovo Nordisk A/S

$38.17

$169.5B

10.91

6.43%

35.35%

59.09%

—

AZNAstraZeneca PLC

$163.33

$126.58B

12.49

8.63%

17.02%

21.72%

—

SNYSanofi

$41.66

$100.03B

11.44

5.49%

8.09%

5.5%

—

NVSNovartis AG

$142.71

$271.25B

19.85

5.97%

22.93%

29.64%

—

GSKGSK plc

$49.71

$99.59B

13.51

4.11%

14.52%

24.99%

—